Spencer S Langerman - JoVE Visualize

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

JAMA Network Open|May 3, 2024

Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLCYichen Lu, Spencer S Langerman, Emily McCain, et al.

Blood Cancer Journal|August 10, 2020

Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysisBenjamin A Derman, Jagoda Jasielec, Spencer S Langerman, et al.

Cancers|November 11, 2022

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple MyelomaBei Wang, Benjamin A Derman, Spencer S Langerman, et al.

Journal of Hematology & Oncology|August 16, 2022

Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myelomaBrian C-H Chiu, Zhou Zhang, Benjamin A Derman, et al.

Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

JAMA Network Open|May 3, 2024

Response- and Progression-Based End Points in Trial and Observational Cohorts of Patients With NSCLCYichen Lu, Spencer S Langerman, Emily McCain, et al.

Blood Cancer Journal|August 10, 2020

Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysisBenjamin A Derman, Jagoda Jasielec, Spencer S Langerman, et al.

Cancers|November 11, 2022

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple MyelomaBei Wang, Benjamin A Derman, Spencer S Langerman, et al.

Journal of Hematology & Oncology|August 16, 2022

Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myelomaBrian C-H Chiu, Zhou Zhang, Benjamin A Derman, et al.

Pageof 1